| __timestamp | BioMarin Pharmaceutical Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 6795238 |
| Thursday, January 1, 2015 | 402271000 | 7454247 |
| Friday, January 1, 2016 | 476593000 | 10345862 |
| Sunday, January 1, 2017 | 554336000 | 16984203 |
| Monday, January 1, 2018 | 604353000 | 16187290 |
| Tuesday, January 1, 2019 | 680924000 | 9299233.54 |
| Wednesday, January 1, 2020 | 737669000 | 19232000 |
| Friday, January 1, 2021 | 759375000 | 23611000 |
| Saturday, January 1, 2022 | 854009000 | 26700000 |
| Sunday, January 1, 2023 | 937300000 | 28215000 |
| Monday, January 1, 2024 | 1009025000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, BioMarin Pharmaceutical Inc. and Summit Therapeutics Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A expenses have surged by over 200% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies. In contrast, Summit Therapeutics has maintained a more conservative growth, with its SG&A expenses increasing by approximately 315% over the same period. This disparity highlights BioMarin's robust market presence compared to Summit's more cautious approach. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into each company's strategic priorities and operational efficiencies.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends